Vsquared Ventures — 2024 Investments
3 investments dated 2024 · listed companies and verified rows first · show all
Kano Therapeutics develops circular single-stranded DNA (cssDNA) as a genetic payload for gene-editing and other DNA-based therapies, offering an alternative to viral vectors and double-stranded DNA.
BiotechDeep TechCambridge, US
Floris Engelhardt(Executive Officer, Director)John Vroom(Director)
BoardAnn DeWitt(Director)in
Co-investorsFifty YearsLaunchpad Venture GroupMetaplanetThe Engine VenturesZAKA VC
Zama provides a protocol that encrypts transaction amounts, balances, and commercial references on public blockchains while keeping addresses public, enabling confidential onchain corporate payments such as cross-border vendor settlement, marketplace payouts, and treasury flows.
AI & Machine LearningCrypto & Web3CybersecurityDeep TechFintechSilicon Valley, FR
Rand Hindi(Founder)in
Co-investorsHack VCLunar VenturesMetaplanetMulticoin CapitalStake CapitalBlockchange Ventures+4 more
Zama provides encryption technology for onchain finance that keeps blockchain addresses public while encrypting transaction amounts and commercial references at the token level.
Crypto & Web3CybersecurityDeep TechFintech
Rand Hindi(Founder)in
Co-investorsMulticoin CapitalSignum CapitalBlockchange VenturesMetaplanetPantera CapitalProtocol Labs+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.